Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides

Biological Chemistry

Volumn 378, Issue 3-4, 1997, Pages 231-237

  Bürgle, Markus ^a   Koppitz, Marcus ^a   Riemer, Christoph ^a   Kessler, Horst ^a   König, Bernhard ^b   Weidle, Ulrich H ^b   Kellermann, Josef ^c   Lottspeich, Friedrich ^c   Graeff, Henner ^d   Schmitt, Manfred ^d   Goretzki, Lothar ^d   Reuning, Ute ^d   Wilhelm, Olaf ^d   Magdolen, Viktor ^d  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Peptides; Receptor; Tumor invasion; uPA

Indexed keywords

UROKINASE;

ARTICLE; CYTOFLUOROMETRY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RECEPTOR BINDING;

EID: 1842296386     PISSN: 14316730     EISSN: None     Source Type: Journal    
DOI: 10.1515/bchm.1997.378.3-4.231     Document Type: Article

References (38)

1. Appella, E., Robinson, E.A., Ullrich, S.J., Stopelli, M., Corti, A., Casani, G., and Blasi, F. (1987). The receptor-binding sequence of urokinase. J. Biol. Chem. 262, 4437-4440.
2. Barlos, K., Chatzi, O., Gatos, D., and Stavropoulos, G. (1991). 2-Chlorotrityl chloride resin. Studies on anchoring of Fmoc-amino acids and peptide cleavage. Int. J. Pept. Protein Res. 37, 513-520.
3. Behrendt, N., Ploug, M., Patthy, L., Houen, G., Blasi, F., and Danø, K. (1991). The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. J. Biol. Chem. 266, 7842-7847.
4. Behrendt, N., Rønne, E., and Danø, K. (1996). Domain interplay in the urokinase receptor. J. Biol. Chem. 271, 22885-22894.
5. Blasi, F. (1993). Urokinase and urokinase receptor: A paracrine/ autocrine system regulating cell migration and invasiveness. BioEssays 15, 105-111.
6. Carpino, L.A., and Han, G.Y. (1972). The fluorenylmethoxycarbonyl amino-protecting group. J. Org. Chem. 37, 3404-3409.
7. Chucholowski, N., Schmitt, M., Rettenberger, P., Schüren, E., Moniwa, N., Goretzki, L., Wilhelm, O., Weidle, U., Jänicke, F., and Graeff, H. (1992). Flow cytoflurometric analysis of the urokinase receptor (uPAR) on tumor cells by flourescent uPA-ligand or monoclonal antibody # 3936. Fibrinolysis 6, Suppl. 4, 95-102.
8. Covey, T.R., Bonner, R.F., Shushan, B.I., and Henion, J. (1988). The determination of protein, oligonucleotide and peptide molecular weights by ion-spray mass spectrometry. Rapid Commun. Mass Spectrom. 2, 249-256.
9. Crowley, C.W., Cohen, R.L., Liu, G., Shuman, M.A., and Levinson, A.D. (1993). Prevention of metastasis by inhibition of the urokinase receptor. Proc. Natl. Acad. Sci. USA 90, 5021-5025.
10. Danø, K., Behrendt, N., Brünner, N., Ellis, V., Ploug, M., and Pyke, C. (1994). The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 8, Suppl. 1, 189-203.
11. Deng, G., Curriden, S.A., Wang, S., Rosenberg, S., and Loskutoff, D.J. (1996). Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J. Cell Biol. 134, 1563-1571.
12. Fazioli, F., and Blasi, F. (1994). Urokinase-type Plasminogen activator and its receptor: new targets for anti-metastatic therapy? Trends Pharmacol. Sci. 15, 25-29.
13. Fenn, J.B., Mann, M., Meng, C.K., Wong, S.F., and Whitehouse, C.M. (1989). Electrospray ionization for mass spectrometry of large biomolecules. Science 246, 64-71.
14. Fields G.B., and Noble R.L. (1990). Solid phase peptide synthesis utilizing 9-fluorenyl-methoxycarbonyl amino acids. Int. J. Peptide Protein Res. 35, 161-214.
15. Goodson, R.J., Doyle, M.V., Kaufman, S.E., and Rosenberg, S. (1994). High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc. Natl. Acad. Sci. USA 91, 7129-7133.
16. Goretzki, L., Bognacki, J., Koppitz, M., Rettenberger, P., Magdolen, V., Creutzburg, S., Hammelburger, J., Weidle, U.H., Wilhelm, O., Kessler, H., Graeff, H., and Schmitt, M. (1997). Quantitative assessment of interaction of urokinase-type plasminogen activator (uPA) and its receptor (CD87) by use of a solid-phase uPA-ligand binding assay. Fibrinolysis Proteolysis, in press.
17. Hansen, A.P., Petros, A.M., Meadows, R.P., Nettesheim, D.G., Mazar, A.P., Olejniczak, E.T., Xu, R.X., Pedersen, T.M., Henkin, J., and Fesik, S.W. (1994). Solution structure of the amino-terminal fragment of urokinase-type plasminogen activator. Biochemistry 33, 4847-4864.
18. Kanse, S.P., Kost, C., Wilhelm, O.G., Andreasen, P., and Preissner, K.T. (1996). The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp. Cell Res. 224, 344-353.
19. Kobayashi, H., Ohi, H., Shinohara, H., Sugimura, M., Fujii, T., Terao, T., Schmitt, M., Goretzki, L., Chucholowski, N., Jänicke, F., and Graeff, H. (1993). Saturation of tumour cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion. Br. J. Cancer 67, 537-544.
20. Luther, T., Magdolen, V., Albrecht, S., Kasper, M., Riemer, C., Kessler, H., Graeff, H., Müller. M., and Schmitt, M. (1997). Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue. Am. J. Pathol., in press.
21. Magdolen, V., Rettenberger, P., Lopens, A., Oi, H., Lottspeich, F., Kellermann, J., Creutzburg, S., Goretzki, L., Weidle, U., Wilhelm, O., Schmitt, M., and Graeff, H. (1995). Expression of the human uPA receptor (uPAR) in E. coli and CHO cells: Purification of the recombinant proteins and generation of polyclonal antibodies in chicken. Electrophoresis 16, 813-816.
22. Magdolen, V., Rettenberger, P., Koppitz, M., Goretzki, L., Kessler, H., Weidle, U.H., König, B., Graeff, H., Schmitt, M., and Wilhelm, O. (1996). Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator. Eur. J. Biochem. 237, 743-751.
23. Møller, L.B., Pöllänen, J., Rønne, E., Pedersen, N., and Blasi, F. (1993). N-linked glycosylation of the ligand binding domain of the human urokinase receptor contributes to the affinity for its ligand. J. Biol. Chem. 268, 11152-11159.
24. Ossowski, L., and Reich, E. (1983). Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 35, 611-619.
25. Pöllänen, J.J. (1993). The N-terminal domain of human urokinase receptor contains two distinct regions critical for ligand recognition. Blood 82, 2719-2729.
26. Ploug, M., Ellis, V., and Danø, K. (1994). Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilo-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor. Biochemistry 33, 8991-8997.
27. Ploug, M., Rahbek-Nielsen, H., Ellis, V., Roepstorff, P., and Danø, K. (1995). Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction. Biochemistry 34, 12524-12534.
28. Rabbani, S.A., Harakidas, P., Davidson, D.J., Henkin, J., and Mazar, A.P. (1995). Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). Int. J. Cancer 63, 840-875.
29. Rettenberger, P., Wilhelm, O., Oi, H., Weidle, U.H., Goretzki, L., Koppitz, M., Lottspeich, F., König, B., Pessara, U., Kramer, M.D., Schmitt, M., and Magdolen, V. (1995). A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor. Biol. Chem. Hoppe-Seyler 376, 587-594.
30. Schmitt, M., Jänicke, F., Moniwa, N., Chucholowski, N., Pache, L., and Graeff, H. (1992). Tumor-associated urokinase-type plasminogen activator: Biological and clinical significance. Biol. Chem. Hoppe-Seyler 373, 611-622.
31. Schmitt, M., Wilhelm, O., Jänicke, F., Magdolen, V., Reuning, U., Ohi, H., Moniwa, N., Kobayashi, H., Weidle, U., and Graeff, H. (1995). Urokinase-type plasminogen activator (uPA) and its receptor (CD87): A new target in tumor invasion and metastasis. J. Obstet. Gynaecol. 21, 151-165.
32. 3 binding to vitronectin. Nature 383, 441-443.
33. Tsugita, A., Uchida, T., Mewes, H.W., and Ataka, T. (1987). A rapid vapor-phase acid (hydrochloric acid and trifluoroacetic acid) hydrolysis of peptide and protein. J. Biochem. 102, 1593-1597.
34. Wei, Y., Lukashev, M., Simon, D.I., Bodary, S.C., Rosenberg, S., Doyle, M.V., Chapman, H.A. (1996). Regulation of integrin function by the urokinase receptor. Science 273, 1551-1555.
35. White P. (1992). Fmoc-Trp(Boc)-OH: A new derivative for the synthesis of peptides containing tryptophan. Peptides, Chemistry and Biology. Proceedings of the 12th American Peptide Symposium. J. A. Smith and J.E. River, eds. (Leiden, The Netherlands: ESCOM Science Publishers), pp. 537-538.
36. Wilhelm, O., Weidle, U., Höhl, S., Rettenberger, P., Schmitt, M., and Graeff, H. (1994). Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA): Inhibition of proliferation and invasion of human ovarian cancer cells. FEBS Lett. 337, 131-134.
37. Wilhelm, O., Schmitt, M., Höhl, S., Senekowitsch, R., and Graeff, H. (1995). Antisense inhibition of urokinase reduces spread of human ovarian cancer cells in mice. Clin. Exp. Metast. 13, 296-302.
38. Xing, R.H., and Rabbani, S.A. (1996). Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis. Int. J. Cancer 67, 423-429.